The heart disease therapy developer completed a $12.7m round that included Alfresa, Dai-ichi Life, Sony Innovation Fund and Japan Lifeline.
Metcela, a Japan-based heart failure treatment developer spun out of Keio University, closed a $12.7m series B round yesterday with a second tranche featuring pharmaceutical firm Alfresa and insurer Dai-ichi Life.
The round was led by University of Tokyo Edge Capital (Utec) Partners, the institution’s venture capital arm, and the second close included science park operator KSP and Makoto Capital, a vehicle for company builder Makoto.
The $4m first tranche closed in April 2020 and featured electronics maker Sony’s…
